<?xml version="1.0" encoding="UTF-8"?><!-- Converted from Majour with majour2a++ V1.5 --><!--Automatically converted from version 2.3 to 2.4-->

<!DOCTYPE Publisher
  PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>

   <PublisherInfo>

      <PublisherName>Springer-Verlag</PublisherName>

      <PublisherLocation>Berlin/Heidelberg</PublisherLocation>

   </PublisherInfo>

   <Journal>

      <JournalInfo JournalProductType="Legacy" NumberingStyle="Unnumbered">

         <JournalID>105</JournalID>

         <JournalPrintISSN>0017-8470</JournalPrintISSN>

         <JournalSPIN/>

         <JournalTitle>Der Hautarzt</JournalTitle>

         <JournalSubTitle>Zeitschrift für Dermatologie, Allergologie, Venerologie und verwandte Gebiete</JournalSubTitle>

         <JournalAbbreviatedTitle>Hautarzt</JournalAbbreviatedTitle>
         <JournalSubjectGroup>
            <JournalSubject Type="Primary">Legacy</JournalSubject>
         </JournalSubjectGroup>

      </JournalInfo>

      <Volume>

         <VolumeInfo VolumeType="Regular">
            <VolumeIDStart>46</VolumeIDStart>
            <VolumeIDEnd>46</VolumeIDEnd>
            <VolumeIssueCount/>
         </VolumeInfo>

         <Issue IssueType="Regular">

            <IssueInfo TocLevels="0">

               <IssueIDStart>7</IssueIDStart>

               <IssueIDEnd>7</IssueIDEnd>

               <IssueHistory>

                  <PrintDate>

                     <Year>1995</Year>

                     <Month>7</Month>

                     <Day>19</Day>

                  </PrintDate>

                  <CoverDate>

                     <Year>1995</Year>

                     <Month>7</Month>

                  </CoverDate>

               </IssueHistory>

               <IssueCopyright>

                  <CopyrightHolderName>Springer-Verlag Berlin Heidelberg</CopyrightHolderName>

                  <CopyrightYear>1995</CopyrightYear>

               </IssueCopyright>

            </IssueInfo>

            <Article ID="Art1">

               <ArticleInfo Language="De" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" ContainsESM="No" TocLevels="0">

                  <ArticleID>50460467.105</ArticleID>

                  <ArticleDOI>10.1007/s001050050283</ArticleDOI>

                  <ArticleTitle Language="De">Sjögren-Lupus erythematodesÜberlappungssyndrom</ArticleTitle>

                  <ArticleSubTitle Language="De"/>

                  <ArticleCategory>ORIGINALIEN</ArticleCategory>

                  <ArticleFirstPage>467</ArticleFirstPage>

                  <ArticleLastPage>471</ArticleLastPage>

                  <ArticleCopyright>

                     <CopyrightHolderName>Springer-Verlag Berlin Heidelberg</CopyrightHolderName>

                     <CopyrightYear>1995</CopyrightYear>

                  </ArticleCopyright>
                  <ArticleGrants>
                     <MetadataGrant Grant="OpenAccess"/>
                     <AbstractGrant Grant="OpenAccess"/>
                     <BodyPDFGrant Grant="Restricted"/>
                     <BodyHTMLGrant Grant="Restricted"/>
                     <BibliographyGrant Grant="Restricted"/>
                     <ESMGrant Grant="Restricted"/>
                  </ArticleGrants>

               </ArticleInfo>

               <ArticleHeader>

                  <AuthorGroup>

                     <Author AffiliationIDS="A1">

                        <AuthorName DisplayOrder="Western">

                           <GivenName>Ralph M.</GivenName>

                           <FamilyName>Trüeb</FamilyName>

                        </AuthorName>

                     </Author>

                     <Author AffiliationIDS="A1">

                        <AuthorName DisplayOrder="Western">

                           <GivenName>Siegfried</GivenName>

                           <FamilyName>Borelli</FamilyName>

                        </AuthorName>

                     </Author>

                     <Author AffiliationIDS="A1">

                        <AuthorName DisplayOrder="Western">

                           <GivenName>Peter</GivenName>

                           <FamilyName>Schmid-Grendelmeier</FamilyName>

                        </AuthorName>

                     </Author>

                     <Author AffiliationIDS="A1">

                        <AuthorName DisplayOrder="Western">

                           <GivenName>Renato G.</GivenName>

                           <FamilyName>Panizzon</FamilyName>

                        </AuthorName>

                     </Author>

                     <InstitutionalAuthor>

                        <InstitutionalAuthorName>and G. Burg</InstitutionalAuthorName>

                     </InstitutionalAuthor>

                     <Author AffiliationIDS="A1">

                        <AuthorName DisplayOrder="Western">

                           <GivenName>Günter</GivenName>

                           <FamilyName>Burg</FamilyName>

                        </AuthorName>

                     </Author>

                     <Affiliation ID="A1">

                        <OrgName>Dermatologische Klinik (Direktor: Prof. Dr. G. Burg), Universitätsspital, Zürich
 </OrgName>

                        <OrgAddress>

                           <Street/>

                           <Postbox/>

                           <Postcode/>

                           <City/>

                           <State/>

                           <Country>XX</Country>

                        </OrgAddress>

                     </Affiliation>

                  </AuthorGroup>

                  <Abstract ID="Abs1" Language="De">

                     <Heading>Zusammenfassung</Heading>

                     <Para/>

                     <Para>

                        <Emphasis Type="Italic">Patienten mit phänotypischer Sjögren-Syndrom (SS)-Lupus erythematodes(LE)-Überlappung stellen eine immungenetisch, serologisch und klinisch einheitliche Krankheitsgruppe dar mit polyzyklisch-anulären, erythematosquamösen Hautläsionen, zirkulierenden SSA(Ro)-Antikörpern und hoher Prävalenz des immungenetischen Phänotyps HLA-DR3. Die Sicca-Symptomatologie des SS kann der LE-Symptomatik zeitlich folgen oder vorangehen. Neben Hautveränderungen wie beim subakuten kutanen LE (SCLE) kommt es zu vaskulitischen, purpuriformen und Sweet-Syndrom-artigen Hautläsionen. Die älteren, vornehmlich weiblichen Patienten zeigen ein erhöhtes Risiko pulmonaler und neurologischer Komplikationen. Demgegenüber kommt es selten zu einer Nierenbeteiligung. Eine 81jährige, anti-SSA(Ro)-, HLA-DR3-positive Frau mit 30jähriger Anamnese eines kutanen LE wird vorgestellt, bei der erst Jahre später neben den Hautveränderungen eines SCLE eine Sicca-Symptomatik, vaskulitische und Sweet-Syndrom-artige Hautveränderungen auftraten. Wenngleich diskutiert werden kann, ob es sich bei der phänotypischen SS-LE-Überlappung um ein eigenständiges Krankheitsbild oder um einen LE mit sekundärem SS bzw. ein primäres SS mit Hautmanifestationen handelt, scheint das SS-LE-Überlappungssyndrom hinreichend gut charakterisiert, um es als eine Krankheitsentität mit eigenen Implikationen für die Therapie und Prognose anzuerkennen. Die Stellung des SS/LE-Überlappungssyndroms im Spektrum der anti-SSA(Ro)-, HLA-DR3-positiven Erkrankungen, und die enge immunologische Verwandtschaft zum SS und zum anti-SSA(Ro)-positiven LE werden diskutiert.</Emphasis>

                     </Para>

                  </Abstract>

                  <Abstract ID="Abs2" Language="En">

                     <Heading>Summary</Heading>

                     <Para/>

                     <Para>Patients with anti-SSA(Ro)-positive Sjögren's syndrome (SS)/lupus erythematosus (LE) overlap are a immunogenetically, serologically and clinically homogeneous group; what they have in common is an increased frequency of the HLA-DR3 phenotype, demonstrating SSA(Ro) antibody activity and the typical annular, polycyclic, erythematous lesions of subacute cutaneous LE. The sicca symptoms of SS may develop long after the cutaneous lesions of LE have been present, or vice versa, as well as vasculitic, purpuric, and Sweet's syndrome-like lesions. The elderly, predominantly female patients are at enhanced risk for pulmonary and neurological disease, but glomerulonephritis occurs infrequently. We present an 81-year-old, SSA(Ro) antibody-positive and HLA-DR3-positive woman with SS/LE overlap syndrome, who had cutaneous LE for 30 years, developing sicca symptoms, vasculitic and Sweet's syndrome-like skin lesions only years after the LE symptoms. Although there is still some discussion as to whether phenotypical SS/LE overlap represents a distinct disease or is secondary SS in SLE or systemic SS with cutaneous involvement, the SS/LE overlap syndrome seems well enough delineated to be considered as a disease entity with separate implications for therapy and prognosis. Its position in the spectrum of anti-SSA(Ro) antibody- and HLA-DR3-positive diseases and its relationship to SS and to anti-SSA(Ro) antibody-positive LE are discussed.
 </Para>

                  </Abstract>

                  <KeywordGroup Language="De">

                     <Keyword>Schlüsselwörter Sjögren-Lupus erythematodes-Überlappungssyndrom</Keyword>

                     <Keyword>HLA DR3</Keyword>

                     <Keyword>Anti-SSA(Ro)-Antikörper</Keyword>

                     <Keyword>Anti-SSA(Ro)-positiver Lupus erythematodes</Keyword>

                     <Keyword>Hautmanifestationen des Sjögren-Syndroms</Keyword>

                  </KeywordGroup>

                  <KeywordGroup Language="En">

                     <Keyword>Key words Sjögren's/lupus erythematosus overlap syndrome</Keyword>

                     <Keyword>HLA DR3 phenotype</Keyword>

                     <Keyword>Anti-SSA(Ro) antibodies</Keyword>

                     <Keyword>Anti-SSA(Ro) antibody-positive lupus erythematosus</Keyword>

                     <Keyword>Cutaneous manifestations of Sjögren's syndrome</Keyword>

                  </KeywordGroup>

                  <ArticleNote Type="Misc">

                     <SimplePara>Eingegangen am 5. April 1994 Angenommen am 24. August 1994</SimplePara>

                  </ArticleNote>

               </ArticleHeader>

               <NoBody/>

            </Article>

         </Issue>

      </Volume>

   </Journal>

</Publisher>